Sarepta Short Term Debt vs Total Liab Analysis

SRPT Stock

USD 114.23 3.73 3.38%

Sarepta Therapeutics financial indicator trend analysis is much more than just breaking down Sarepta Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sarepta Therapeutics is a good investment. Please check the relationship between Sarepta Therapeutics Short Term Debt and its Total Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Short Term Debt vs Total Liab

Short Term Debt vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sarepta Therapeutics Short Term Debt account and Total Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between Sarepta Therapeutics' Short Term Debt and Total Liab is 0.7. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Total Liab in the same time period over historical financial statements of Sarepta Therapeutics, assuming nothing else is changed. The correlation between historical values of Sarepta Therapeutics' Short Term Debt and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Sarepta Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Short Term Debt i.e., Sarepta Therapeutics' Short Term Debt and Total Liab go up and down completely randomly.

Correlation Coefficient

0.7

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Short Term Debt

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Sarepta Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sarepta Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.At this time, Sarepta Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 30.6 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (23.62) in 2024.

	2023	2024 (projected)
Non Recurring	199.2M	209.2M
Interest Income	67.7M	71.0M

Non Recurring Interest Income

Sarepta Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock	Non Current Liabilities Total	Other Current Assets	Other Assets	Property Plant Equipment	Net Receivables
Total Assets		0.66	0.96	0.79	0.96	0.34	-0.97	0.9	0.69	0.98	0.81	0.98	-0.3	0.94	0.75	0.98	0.98	0.93	1.0	0.78	-0.3	0.98	0.69	0.63	0.97	0.86
Other Current Liab	0.66		0.79	0.3	0.69	0.77	-0.77	0.72	0.12	0.72	0.82	0.57	-0.2	0.67	0.79	0.72	0.71	0.76	0.64	0.57	-0.2	0.69	0.79	0.22	0.76	0.8
Total Current Liabilities	0.96	0.79		0.63	0.97	0.53	-0.99	0.95	0.52	0.99	0.9	0.89	-0.27	0.89	0.8	0.97	0.98	0.99	0.94	0.79	-0.27	0.96	0.79	0.51	0.99	0.95
Total Stockholder Equity	0.79	0.3	0.63		0.7	0.11	-0.71	0.63	0.58	0.71	0.51	0.81	-0.38	0.84	0.61	0.8	0.64	0.63	0.8	0.76	-0.38	0.64	0.52	0.4	0.69	0.57
Property Plant And Equipment Net	0.96	0.69	0.97	0.7		0.48	-0.97	0.98	0.54	0.99	0.82	0.89	-0.26	0.9	0.78	0.97	0.96	0.98	0.95	0.85	-0.26	0.94	0.73	0.49	0.99	0.94
Net Debt	0.34	0.77	0.53	0.11	0.48		-0.5	0.58	-0.42	0.45	0.7	0.2	-0.01	0.37	0.82	0.46	0.39	0.56	0.31	0.56	-0.01	0.34	0.85	-0.31	0.53	0.69
Retained Earnings	-0.97	-0.77	-0.99	-0.71	-0.97	-0.5		-0.95	-0.56	-0.99	-0.88	-0.91	0.33	-0.94	-0.81	-0.99	-0.97	-0.97	-0.96	-0.82	0.33	-0.95	-0.77	-0.51	-0.99	-0.93
Accounts Payable	0.9	0.72	0.95	0.63	0.98	0.58	-0.95		0.4	0.96	0.82	0.8	-0.26	0.86	0.81	0.94	0.91	0.97	0.88	0.87	-0.26	0.88	0.77	0.35	0.97	0.96
Cash	0.69	0.12	0.52	0.58	0.54	-0.42	-0.56	0.4		0.59	0.26	0.79	-0.24	0.59	0.07	0.56	0.67	0.47	0.71	0.24	-0.24	0.7	0.0	0.9	0.53	0.29
Non Current Assets Total	0.98	0.72	0.99	0.71	0.99	0.45	-0.99	0.96	0.59		0.85	0.92	-0.26	0.91	0.76	0.98	0.98	0.98	0.96	0.81	-0.26	0.97	0.73	0.55	0.99	0.93
Non Currrent Assets Other	0.81	0.82	0.9	0.51	0.82	0.7	-0.88	0.82	0.26	0.85		0.73	-0.19	0.76	0.87	0.85	0.84	0.9	0.79	0.72	-0.19	0.81	0.93	0.27	0.89	0.92
Cash And Short Term Investments	0.98	0.57	0.89	0.81	0.89	0.2	-0.91	0.8	0.79	0.92	0.73		-0.32	0.92	0.66	0.93	0.95	0.85	0.99	0.68	-0.32	0.96	0.6	0.73	0.9	0.75
Common Stock Total Equity	-0.3	-0.2	-0.27	-0.38	-0.26	-0.01	0.33	-0.26	-0.24	-0.26	-0.19	-0.32		-0.53	-0.24	-0.36	-0.24	-0.23	-0.31	-0.35	1.0	-0.23	-0.18	-0.17	-0.27	-0.19
Common Stock Shares Outstanding	0.94	0.67	0.89	0.84	0.9	0.37	-0.94	0.86	0.59	0.91	0.76	0.92	-0.53		0.77	0.97	0.88	0.87	0.94	0.81	-0.53	0.87	0.69	0.53	0.92	0.8
Short Term Investments	0.75	0.79	0.8	0.61	0.78	0.82	-0.81	0.81	0.07	0.76	0.87	0.66	-0.24	0.77		0.82	0.72	0.8	0.74	0.79	-0.24	0.69	0.97	0.1	0.82	0.85
Other Stockholder Equity	0.98	0.72	0.97	0.8	0.97	0.46	-0.99	0.94	0.56	0.98	0.85	0.93	-0.36	0.97	0.82		0.95	0.96	0.97	0.86	-0.36	0.93	0.77	0.49	0.98	0.92
Total Liab	0.98	0.71	0.98	0.64	0.96	0.39	-0.97	0.91	0.67	0.98	0.84	0.95	-0.24	0.88	0.72	0.95		0.95	0.97	0.71	-0.24	1.0	0.69	0.65	0.97	0.88
Property Plant And Equipment Gross	0.93	0.76	0.99	0.63	0.98	0.56	-0.97	0.97	0.47	0.98	0.9	0.85	-0.23	0.87	0.8	0.96	0.95		0.92	0.85	-0.23	0.93	0.8	0.4	0.99	0.98
Total Current Assets	1.0	0.64	0.94	0.8	0.95	0.31	-0.96	0.88	0.71	0.96	0.79	0.99	-0.31	0.94	0.74	0.97	0.97	0.92		0.76	-0.31	0.97	0.68	0.65	0.95	0.84
Intangible Assets	0.78	0.57	0.79	0.76	0.85	0.56	-0.82	0.87	0.24	0.81	0.72	0.68	-0.35	0.81	0.79	0.86	0.71	0.85	0.76		-0.35	0.68	0.77	0.04	0.82	0.88
Common Stock	-0.3	-0.2	-0.27	-0.38	-0.26	-0.01	0.33	-0.26	-0.24	-0.26	-0.19	-0.32	1.0	-0.53	-0.24	-0.36	-0.24	-0.23	-0.31	-0.35		-0.23	-0.18	-0.17	-0.27	-0.19
Non Current Liabilities Total	0.98	0.69	0.96	0.64	0.94	0.34	-0.95	0.88	0.7	0.97	0.81	0.96	-0.23	0.87	0.69	0.93	1.0	0.93	0.97	0.68	-0.23		0.65	0.69	0.96	0.85
Other Current Assets	0.69	0.79	0.79	0.52	0.73	0.85	-0.77	0.77	0.0	0.73	0.93	0.6	-0.18	0.69	0.97	0.77	0.69	0.8	0.68	0.77	-0.18	0.65		0.01	0.79	0.87
Other Assets	0.63	0.22	0.51	0.4	0.49	-0.31	-0.51	0.35	0.9	0.55	0.27	0.73	-0.17	0.53	0.1	0.49	0.65	0.4	0.65	0.04	-0.17	0.69	0.01		0.5	0.22
Property Plant Equipment	0.97	0.76	0.99	0.69	0.99	0.53	-0.99	0.97	0.53	0.99	0.89	0.9	-0.27	0.92	0.82	0.98	0.97	0.99	0.95	0.82	-0.27	0.96	0.79	0.5		0.94
Net Receivables	0.86	0.8	0.95	0.57	0.94	0.69	-0.93	0.96	0.29	0.93	0.92	0.75	-0.19	0.8	0.85	0.92	0.88	0.98	0.84	0.88	-0.19	0.85	0.87	0.22	0.94

Click cells to compare fundamentals

Sarepta Therapeutics Account Relationship Matchups

Sarepta Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.8B	3.0B	3.1B	3.1B	3.3B	3.4B
Other Current Liab	196.7M	22.1M	15.1M	406.5M	283.4M	297.6M
Total Current Liabilities	264.8M	416.0M	452.7M	619.6M	653.7M	686.3M
Total Stockholder Equity	818.2M	761.8M	928.0M	385.0M	859.3M	902.3M
Property Plant And Equipment Net	167.6M	282.2M	236.7M	245.0M	357.1M	375.0M
Net Debt	(105.5M)	(429.8M)	(977.5M)	650.6M	968.4M	1.0B
Retained Earnings	(2.3B)	(2.8B)	(3.2B)	(3.9B)	(4.4B)	(4.2B)
Accounts Payable	68.1M	111.1M	76.7M	95.9M	164.9M	173.2M
Cash	835.1M	1.5B	2.1B	966.8M	428.4M	298.4M
Non Current Assets Total	353.9M	499.5M	543.9M	570.5M	685.2M	719.5M
Non Currrent Assets Other	11.8M	13.0M	143.3M	286.6M	276.4M	290.2M
Cash And Short Term Investments	1.1B	1.9B	2.1B	2.0B	1.7B	1.8B
Common Stock Total Equity	6K	7K	8K	9K	8.1K	7.7K
Common Stock Shares Outstanding	73.6M	78.0M	81.3M	87.6M	92.4M	97.0M
Short Term Investments	803.1M	289.7M	435.9M	1.0B	1.2B	1.3B
Liabilities And Stockholders Equity	1.8B	3.0B	3.1B	3.1B	3.3B	3.4B
Other Stockholder Equity	3.1B	3.6B	4.1B	4.3B	5.3B	5.6B
Total Liab	1.0B	2.2B	2.2B	2.7B	2.4B	2.5B
Property Plant And Equipment Gross	167.6M	282.2M	349.3M	393.9M	548.1M	575.5M
Total Current Assets	1.5B	2.5B	2.6B	2.6B	2.6B	2.7B
Accumulated Other Comprehensive Income	50K	3K	(20K)	(1.7M)	918K	963.9K
Intangible Assets	12.5M	13.6M	14.2M	7.6M	29.6M	31.1M
Common Stock	6K	7K	8K	9K	8.1K	7.7K
Non Current Liabilities Total	739.9M	1.8B	1.8B	2.1B	1.8B	1.8B
Other Current Assets	5.2M	4.1M	6.1M	108.1M	140.5M	147.5M
Other Assets	141.9M	295.5M	292.9M	286.6M	1.0	0.95
Property Plant Equipment	129.6M	190.4M	191.2M	245.0M	281.7M	295.8M
Net Receivables	93.9M	138.6M	171.6M	259.7M	439.7M	461.7M
Short Long Term Debt Total	729.6M	1.2B	1.4B	1.6B	1.4B	1.5B
Other Liab	10.2M	734.1M	628.8M	521.9M	600.2M	630.2M
Long Term Debt	681.9M	992.5M	1.1B	1.5B	1.1B	1.2B
Short Term Debt	7.8M	193.6M	271.7M	15.5M	141.2M	148.2M
Net Tangible Assets	805.7M	748.1M	913.8M	377.4M	434.0M	530.3M
Retained Earnings Total Equity	(1.6B)	(2.3B)	(2.8B)	(3.2B)	(2.9B)	(2.7B)
Long Term Debt Total	420.6M	681.9M	992.5M	1.1B	1.3B	1.3B
Capital Surpluse	2.6B	3.1B	3.6B	4.1B	4.8B	5.0B
Inventory	171.4M	232.0M	186.2M	204.0M	322.9M	339.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC